Abstract

The present invention relates to a novel antibody drug conjugate and, specifically, to an antibody drug conjugate comprising polyethylene glycol, a solvate thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, wherein the conjugate has excellent physical properties and stability.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment

Abstract

The present application relates to an antibody-drug conjugate and a use thereof.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present application relates to a method of increasing the production yield of an antibody comprising a functional group using a thiol-reactive additive.

IPC Classes  ?

• C07K 1/06 - General processes for the preparation of peptides using protecting groups or activating agents
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes

Abstract

Some aspects of the present application provide a compound comprising an Fc-binding unit. The compound comprising an Fc-binding unit, of the present application, can be used for site-specific delivery of a target group to an antibody. In addition, some aspects of the present application provide a method for preparing an antibody conjugate comprising a target group (for example, a reactive group) by using a compound comprising an Fc-binding unit.

IPC Classes  ?

• C07K 7/02 - Linear peptides containing at least one abnormal peptide link
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Abstract

Some embodiments of the present application provide a compound comprising Fc binding unit. The compound comprising Fc binding unit of the present application may be used to transfer a group of interest to an antibody in a position-specific manner. Furthermore, some embodiments of the present application provide a method for preparing an antibody conjugate comprising a group of interest (for example, a reactive group) using the compound comprising Fc binding unit.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment

Abstract

The present application relates to an antibody-drug conjugate and use thereof.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Some aspects of the present application provide a compound comprising an Fc-binding unit. The compound comprising an Fc-binding unit, of the present application, can be used for site-specific delivery of a group of interest to an antibody. In addition, some aspects of the present application provide a method for preparing an antibody conjugate, comprising a group of interest (for example, a reactive group), by using a compound comprising an Fc-binding unit.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present application pertains to a method for increasing the production yield of an antibody containing a functional group by using a thiol-reactive additive.

IPC Classes  ?

• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment

Abstract

The present invention relates to a novel antibody drug conjugate and, specifically, to an antibody drug conjugate comprising polyethylene glycol, a solvate thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing same, wherein the conjugate has excellent physical properties and stability.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• A61K 38/05 - Dipeptides

Abstract

The present invention relates to technology capable of labeling a certain site of an antibody with a certain number of chemical functional groups or cargo moieties. The present invention may provide an antibody product having high uniformity. The present invention may provide an antibody product whose antibody functions are not degraded. That is, the present invention may provide an antibody product whose antibody binding affinity and half-life are not degraded. The present invention is of great significance as being the first technology allowing site-specific labeling of an antibody without any complicated processes.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07D 207/46 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment

Abstract

The present invention relates to technology capable of labeling a certain site of an antibody with a certain number of chemical functional groups or cargo moieties. The present invention may provide an antibody product having high uniformity. The present invention may provide an antibody product whose antibody functions are not degraded. That is, the present invention may provide an antibody product whose antibody binding affinity and half-life are not degraded. The present invention is of great significance as being the first technology allowing site-specific labeling of an antibody without any complicated processes.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C07D 207/46 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes

Abstract

The present application relates to a novel linker for use in bioconjugation, comprising two or more electrophilic carbon atoms of a carbonyl group, and a click chemistry functional group and, more specifically, to a linker through which a compound, a peptide, and/or a protein can be directly and/or indirectly linked by a substitution reaction to a desired target molecule, that is, a target molecule.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 31/537 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Abstract

The present invention pertains to the use of a coenzyme Q10 solubilizing composition for treating immune diseases. CoQ10 micelles, in which a coenzyme C10 according to the present invention is encapsulated, were found to inhibit the infiltration of inflammatory cells. In addition, the coenzyme Q10 solubilizing composition was found to inhibit the expression of inflammatory cytokines and increase the expression of anti-inflammatory cytokines, thus having therapeutic effects on rheumatoid arthritis, osteoarthritis, Sjogren's syndrome, and rheumatic diseases accompanying obesity. Therefore, the coenzyme Q10 solubilizing composition can be advantageously used for preventing or treating immune diseases.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61P 37/00 - Drugs for immunological or allergic disorders
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23P 10/30 - Encapsulation of particles, e.g. foodstuff additives

Abstract

The present application relates to a technology enabling a specific number of chemical functional groups or cargo moieties to be labeled at specific sites of an antibody. An antibody product having high uniformity can be provided by the present application. In addition, an antibody product in which functions of the antibody do not decline can be provided by the present application. That is, an antibody product of which avidity and half-life do not decline can be provided. The present application is very meaningful by being the first technology that enables site-specific labeling of antibodies without a complicated process.

IPC Classes  ?

• C07D 207/46 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present application relates to a technology enabling a specific number of chemical functional groups or cargo moieties to be labeled at specific sites of an antibody. An antibody product having high uniformity can be provided by the present application. In addition, an antibody product in which functions of the antibody do not decline can be provided by the present application. That is, an antibody product of which avidity and half-life do not decline can be provided. The present application is very meaningful by being the first technology that enables site-specific labeling of antibodies without a complicated process.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C07D 207/46 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present application pertains to a novel linker for use in bioconjugation, containing two or more electrophilic carbon atoms of a carbonyl group, and a click chemistry functional group and, more specifically, to a linker through which a compound, a peptide, and/or a protein can be directly and/or indirectly linked by a substitution reaction to a desired target molecule, that is, a target molecule.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C07D 207/46 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom

Abstract

The present application pertains to a novel linker for use in bioconjugation, containing two or more electrophilic carbon atoms of a carbonyl group, and a click chemistry functional group and, more specifically, to a linker through which a compound, a peptide, and/or a protein can be directly and/or indirectly linked by a substitution reaction to a desired target molecule, that is, a target molecule.

IPC Classes  ?

• C07D 207/46 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents

Goods & Services

Dietary food supplements containing DHA; dietary supplements based on liquorice extracts; non-prescription medicines; dietetic food supplements; nutritional supplements; food supplements for medical purposes; dietary and nutritionally fortified food products adapted for medical purposes; nutraceuticals for therapeutic purposes; nutraceutical preparations for therapeutic or medical purposes; dietary supplements based on Coenzyme Q10.

Goods & Services

Pharmaceutical agents affecting metabolism; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of cancer; chemical preparations for pharmaceutical purposes; biotechnological preparations for medical purposes; drugs for medical purposes; antibodies for medical purposes; pharmaceutical compositions; medicines for human purposes; nutraceuticals for therapeutic purposes; therapeutic drugs and agents; anti-cancer preparations. Research and development of vaccines and medicines; biotechnology research; biological research; crude medicines research; scientific research for medical purposes in the field of cancerous diseases; research on the subject of pharmaceuticals; medical research; clinical research.

Goods & Services

Pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations; lozenges for pharmaceutical purposes; cachets for pharmaceutical purposes; biotechnological preparations for medical purposes; reagents for medical use; drugs for medical purposes; antibodies for medical purposes; medicines for human purposes; anti-cancer preparations; chemically modified antibody.

Goods & Services

Pharmaceutical agents affecting metabolism; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of cancer; chemical preparations for pharmaceutical purposes, namely, for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; biotechnological preparations for medical purposes, namely, for the treatment of oncological, metabolic and ophthalmic diseases and disorders; drugs for medical purposes, namely, for treating cancer; drugs for medical purposes, namely, for treating diabetes; drugs for medical purposes, namely, for treating ocular disease; antibodies for medical purposes, namely, for the treatment of oncological, metabolic and ophthalmic diseases and disorders; pharmaceutical compositions for the treatment of oncological, metabolic and ophthalmic diseases and disorders; medicines for human purposes for the treatment of oncological, metabolic and ophthalmic diseases and disorders; nutraceuticals for therapeutic purposes for the treatment of cancer; nutraceuticals for therapeutic purposes for the treatment of diabetes; therapeutic drugs and agents, namely, antibody drug conjugate comprising antibody and chemical compound attached for the treatment of oncological, metabolic and ophthalmic diseases and disorders; anti-cancer preparations Research and development of vaccines and medicines; biotechnology research; biological research; crude medicines research; scientific research for medical purposes in the field of cancerous diseases; research on the subject of pharmaceuticals; medical research; clinical research in the field of oncology, metabolic disease and ophthalmology

Goods & Services

Pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for the treatment of oncological, metabolic and ophthalmic diseases and disorders; lozenges for pharmaceutical purposes for the treatment of oncological, metabolic and ophthalmic diseases and disorders; cachets for pharmaceutical purposes for the treatment of oncological, metabolic and ophthalmic diseases and disorders; biotechnological preparations for medical purposes for the treatment of oncological, metabolic and ophthalmic diseases and disorders; reagents for medical use; drugs for medical purposes for the treatment of oncological, metabolic and ophthalmic diseases and disorders; antibodies for medical purposes for the treatment and diagnosis of oncological, metabolic and ophthalmic diseases and disorders; medicines for human purposes for the treatment of oncological, metabolic and ophthalmic diseases and disorders; anti-cancer preparations; chemically modified antibodies for the treatment and diagnosis of oncological, metabolic and ophthalmic diseases and disorders

Goods & Services

Dietary food supplements containing DHA; dietary supplements based on liquorice extracts; non-prescription medicines for treating fatigue; non-prescription medicines for use in treating rheumatoid arthritis and osteoarthritis; dietetic food supplements; nutritional supplements; food supplements for medical purposes; dietary and nutritionally fortified food products adapted for medical purposes for relieving pain; dietary and nutritionally fortified food products adapted for medical purposes for promoting blood circulation; dietary and nutritionally fortified food products adapted for medical purposes for boosting immune system; nutraceuticals for therapeutic purposes for making antioxidant effects; nutraceuticals for therapeutic purposes for helping anti-inflammatory activities; nutraceuticals for therapeutic purposes for helping antidotal effect; nutraceutical preparations for therapeutic or medical purposes for stomach support; nutraceutical preparations for therapeutic or medical purposes for the treatment of rheumatoid arthritis and osteoarthritis; nutraceutical preparations for therapeutic or medical purposes for use in weight reduction; dietary supplements based on Coenzyme Q10

Abstract

The present invention relates to a coenzyme Q10 solubilizing composition and a method for preparing the same. In the coenzyme Q10 solubilizing composition and the method for preparing the same according to the present invention, coenzyme Q10, which is a non-soluble drug, is encapsulated by a micelle containing glycyrrhizic acid or a salt of glycyrrhizic acid, bile acid, and unsaturated fatty acid, thereby improving encapsulation efficiency and improving the solubility of coenzyme Q10 in water. In addition, the mass-production of the composition can be easily achieved through sonication or a microfluidizer, the particle size of the composition encapsulating coenzyme Q10 can be controlled, and the natural substance-based formulation without using ethanol and an organic solvent are possible, so that it is expected that the composition of the present invention can be favorably utilized as a composition for pharmaceuticals, foods, and cosmetics, the composition having ensured stability and almost no toxicity.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 8/63 - SteroidsDerivatives thereof
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 8/14 - Liposomes
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 8/67 - Vitamins
• A61Q 19/00 - Preparations for care of the skin
• A61K 9/107 - Emulsions
• A61K 8/36 - Carboxylic acidsSalts or anhydrides thereof
• A61K 8/34 - Alcohols
• A61K 8/35 - Ketones, e.g. quinones, benzophenone
• A61K 8/60 - SugarsDerivatives thereof
• A61K 9/19 - Particulate form, e.g. powders lyophilised

Abstract

A peptide of the present invention has a modified affinity binding to IgG by substitution of an amino acid at a certain position in an amino acid sequence with a different amino acid, and thus can find useful applications in IgG immobilization or purification. In addition, the peptide with improved affinity binding to IgG according to the preset invention can be usefully used in IgG purification columns because the peptide retains outstanding purification ability even after a plurality of repeated rounds of usage in addition to being superior in terms of affinity binding to IgG and allowing for the elution of IgG under a mild pH condition.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 1/14 - ExtractionSeparationPurification
• C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum

Abstract

The present invention relates to a coenzyme Q10 solubilizing composition and a method for preparing the same. In the coenzyme Q10 solubilizing composition and the method for preparing the same according to the present invention, coenzyme Q10, which is a non-soluble drug, is encapsulated by a micelle containing glycyrrhizic acid or a salt of glycyrrhizic acid, bile acid, and unsaturated fatty acid, thereby improving encapsulation efficiency and improving the solubility of coenzyme Q10 in water. In addition, the mass-production of the composition can be easily achieved through sonication or a microfluidizer, the particle size of the composition encapsulating coenzyme Q10 can be controlled, and the natural substance-based formulation without using ethanol and an organic solvent are possible, so that it is expected that the composition of the present invention can be favorably utilized as a composition for pharmaceuticals, foods, and cosmetics, the composition having ensured stability and almost no toxicity.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 8/35 - Ketones, e.g. quinones, benzophenone
• A61K 8/60 - SugarsDerivatives thereof
• A61K 8/63 - SteroidsDerivatives thereof